Suven Life Sciences - 2026 Company Profile, Team

About Suven Life Sciences

Suven Life Sciences is a publicly listed company based in Hyderabad (India) founded in 1989. CDMO services and CNS drug discovery pipeline are offered. The company has 236 employees. Suven Life Sciences has completed 2 acquisitions, including Asian Clinical Trials and Rising Pharmaceuticals. Its Indian entity Suven Life Sciences Limited reported revenue of ₹21.04 Cr. Suven Life Sciences offers products and services including Drug Discovery Services, Masupirdine, Samelisant, and Analytical Chemistry Services. Its focus areas include Diversified Pharmaceuticals.

Company details

Suven Life Sciences offers a suite of services that include CRAMS, drug discovery (includes internal discovery with their own pipeline) and development support services (DDDSS) and formulation development manufacturing services (FDC) for small molecules. They offer a full range of services in drug discovery, development, and manufacturing. Through their CRAMS services, they offer medicinal chemistry services (Lead optimization, Intermediates Building blocks), preclinical and clinical development support, (custom synthesis, scale-up from g to kg etc.,) and API, intermediate and formulation manufacturing services. They claim to have partnerships with 60 innovator pharma companies for CRAMS initiatives and have completed 600 projects. As part of their DDDSS, they offer bioanalytical services (BABE, SADMAD, toxicology studies etc.), PKPD and ADME services. As part of their FDC services they offer analytical method development validation, stability studies etc., Their facilities have been approved for API and intermediate production by the FDA (formulations also), EDQM, MHRA, and PMDA. The company has a CNS drug discovery collaboration with Eli Lilly. Suven has 11 drugs with out-licensing potential. Suven claims to have partnerships with 61 innovator pharma companies for CRAMS initiatives. The company has 41 product patents and 15 process patents as of Jun-2016 in both developed and developing countries.

Headquarters Hyderabad, India
Employees 236
Stage Public
Sectors
Healthcare
Website category Health · Biotechnology and Pharmaceuticals
Email
••••••••
Website suven.com
Social LinkedIn
Legal Name Suven Life Sciences Limited

Operational Areas

Healthcare → Pharmaceuticals & Distribution

Key Metrics

Market Cap
₹7,802 Cr
SUVEN · NSE
Share Price
₹264.85
-4.07% today
Revenue
₹7.11 Cr
FY 2025-26 · +6.8% YoY
EBITDA
−₹284 Cr
Margin -3,999.4%
Net Profit
−₹286 Cr
FY 2025-26 · -72.5% YoY
Debt / Equity
0.02
Interest cover -0.1x
Employee Count
236
Investments & Acquisitions
Asian Clinical Trials
& 1 more

Associated legal entities of Suven Life Sciences

Suven Life Sciences operates through Suven Life Sciences Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.

Legal entity	Status	Incorporated	Registered in	Revenue (FY 2026)	Employees	Directors	Company page
Suven Life Sciences Limited Listed CIN L24110TG1989PLC009713	Active	09 Mar 1989	Hyderabad, Telangana	₹21.0 Cr	137	8	View details

Products & Services of Suven Life Sciences

Suven Life Sciences offers a comprehensive portfolio of products and services, including Drug Discovery Services, Masupirdine, Samelisant, and Analytical Chemistry Services.

Drug Discovery Services

Support Services

Offers synthetic and medicinal chemistry for drug development.

Masupirdine

Drug Candidate

Targets cognitive deficits in Alzheimer's disease.

Samelisant

Drug Candidate

Addresses narcolepsy and cognitive disorders.

Analytical Chemistry Services

Support Services

Provides testing for drug discovery processes.

Board of directors of Suven Life Sciences Limited (Suven Life Sciences)

Suven Life Sciences Limited is the primary company behind Suven Life Sciences. The board of Suven Life Sciences Limited currently have 6 directors; the longest-serving is Venkateswarlu Jasti, appointed in 2010. 20 earlier directors have ceased.

Director	Designation	Appointed	Tenure	Entity
Venkateswarlu Jasti DIN 00278028	Managing Director	04 Jan 2010	16 yrs 10 mo	Suven Life Sciences Limited
Seyed Ehtesham Hasnain DIN 02205199	Director	30 Apr 2010	16 yrs 6 mo	Suven Life Sciences Limited
Sudharani Jasti DIN 00277998	Whole-time director	04 Jan 2013	13 yrs 10 mo	Suven Life Sciences Limited
Santanu Mukherjee DIN 07716452	Director	15 May 2018	8 yrs 5 mo	Suven Life Sciences Limited
Ananthasai Padmaja Jasthi DIN 07484630	Director	14 Nov 2018	7 yrs 11 mo	Suven Life Sciences Limited
Vajja Sambasiva Rao DIN 09233939	Director	30 Jan 2024	2 yrs 9 mo	Suven Life Sciences Limited

People of Suven Life Sciences

50 people are tracked at Suven Life Sciences (5 in leadership, 4 in board & advisors, 41 in team); the tracked headcount is 236.

Name	Role	Group
Sudharani Jasti	Wholetime Director	Leadership
Venkat Jasti	Chairman & CEO	Leadership
Vinod Goyal Dvm, Mvsc, Dabt	Vice President	Leadership
Abdul Rasheed Mohammed	Chief Scientist	Leadership
Jyothsna Ravula	Chief Scientist - Intellectual Property & Regulatory	Leadership
J.A.S. Padmaja	Director	Board & advisors
M. Gopalakrishna	Director	Board & advisors
Santanu Mukherjee	Director	Board & advisors
Syed E. Hasnain	Director	Board & advisors
Akhil Babu	Senior Research Associate	Team
Mahender Reddy	Senior Research Assistant	Team
Shantaveer Irappanavar	Scientist	Team
Srinivas Reddy	Lab Assistant	Team
Mohan P	Associate Scientist	Team
Chinna Goud	Senior Research Associate	Team
M.v.sc; Dabt Santosh Kumar Pandey	Sr. Scientist- Toxicology	Team
Shaik Farooq Basha	Senior Research Associate	Team
Manuraj Ts	Associate Scientist	Team
Vamsi B	Senior Research Associate	Team
Praneshwar Mane	Junior Scientist	Team

30 more people are available in the full profile.

Premium access

Complete people profiles for Suven Life Sciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

Full employee list
Team structure
Board tenure
Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Suven Life Sciences

Suven Life Sciences is a publicly listed company on the NSE with ticker symbol SUVEN in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

IPO date23 Oct 2003
Listed onNSE: SUVEN
Listed entitySuven Life Sciences Limited
Exchange sectorHealth technology
ISININE495B01038
Share price₹281.80 (-0.69% on the day) · 2026-10-14
Market capitalisation₹8,022 Cr
EPS (diluted, trailing year)₹-14.21
Volume (last session)171,969

Financials of Suven Life Sciences

Exchange-reported figures of Suven Life Sciences Limited, the listed company behind Suven Life Sciences (NSE: SUVEN).

Financial Highlights

FY 2025-26 · Consolidated

Revenue

₹7.11 Cr

+6.8% YoY

EBITDA

−₹284 Cr

-71.7% YoY

Profit After Tax

−₹286 Cr

-72.5% YoY

Net Worth

₹591 Cr

+437.7% YoY

Total Assets

₹610 Cr

+446.1% YoY

Total Debt

₹16.69 Cr

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Income statement
Revenue	7.11	6.66	11.69	13.54	11.84	13.48	14.41
Revenue growth	+6.8%	-43.0%	-13.7%	+14.4%	-12.2%	-6.5%	-
EBITDA	(284)	(166)	(128)	(126)	(122)	(79.95)	(116)
EBITDA margin	-3999.4%	-2487.2%	-1093.8%	-928.7%	-1032.5%	-593.1%	-803.0%
Profit before tax	(276)	(161)	(106)	(118)	(122)	(77.49)	(106)
Net profit	(286)	(166)	(117)	(126)	(126)	(72.23)	(94.71)
Net profit margin	-4021.0%	-2488.3%	-1001.6%	-930.9%	-1064.0%	-535.8%	-657.3%
EPS (₹)	(10.48)	(7.37)	(4.82)	(5.42)	(8.39)	(5.67)	(7.40)
Balance sheet
Total assets	610	112	272	379	101	115	152
Net worth	591	110	270	375	96.15	108	143
Total debt	16.69	0.00	0.71	1.61	3.21	4.76	6.01
Cash & bank	337	37.73	164	184	5.52	46.65	15.09
Net working capital	352	29.71	168	195	14.75	88.73	41.43
Cash flow
Cash from operations	(300)	(155)	(115)	(116)	(128)	(96.02)	(135)
Cash from investing	(462)	155	94.44	(248)	(22.23)	55.84	146
Cash from financing	757	(0.76)	(1.05)	396	146	34.86	2.81

Particulars	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Revenue	1.20	3.57	1.52	2.81	0.92	1.87	1.47	1.61
Revenue growth (YoY)	+30.4%	+90.9%	+3.4%	+74.5%	-64.2%	+85.2%	-	-
Other income	6.73	7.52	6.78	2.77	3.78	0.60	1.22	1.63
EBITDA	(111)	(132)	(50.63)	(103)	(79.77)	(50.75)	(43.82)	(39.21)
EBITDA margin	-9243.3%	-3711.5%	-3330.9%	-3677.9%	-8670.7%	-2713.9%	-2981.0%	-2435.4%
Depreciation	2.30	2.16	1.58	1.35	1.32	1.37	1.35	1.53
Interest	0.46	0.48	0.16	0.00	0.00	0.00	0.00	0.01
Profit before tax	(107)	(128)	(45.59)	(102)	(77.31)	(51.52)	(43.95)	(39.12)
Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net profit	(107)	(128)	(45.59)	(102)	(77.31)	(51.52)	(43.95)	(39.12)
EPS (₹)	(3.77)	(4.84)	(2.02)	(4.55)	(3.48)	(2.36)	(2.02)	(1.79)

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Income statement
Revenue	7.11	6.66	11.69	13.54	11.84	13.48	14.41
Revenue growth	+6.8%	-43.0%	-13.7%	+14.4%	-12.2%	-6.5%	-
EBITDA	(62.91)	(51.83)	(30.85)	(27.63)	(36.52)	(30.45)	(35.27)
EBITDA margin	-884.8%	-778.2%	-263.9%	-204.1%	-308.5%	-225.9%	-244.8%
Profit before tax	(54.87)	(47.07)	(9.00)	(20.12)	(36.23)	(27.96)	(25.94)
Net profit	(64.41)	(52.05)	(20.01)	(27.91)	(36.50)	(22.70)	(14.26)
Net profit margin	-905.9%	-781.5%	-171.2%	-206.1%	-308.3%	-168.4%	-99.0%
EPS (₹)	(2.08)	(2.16)	(0.37)	(0.92)	(2.49)	(1.78)	(1.08)
Balance sheet
Total assets	1,522	801	847	857	481	408	396
Net worth	1,503	800	845	853	476	402	388
Total debt	16.69	0.00	0.71	1.61	3.21	4.76	6.01
Cash & bank	331	19.96	153	174	3.15	38.59	1.12
Net working capital	351	27.76	166	191	13.89	87.35	43.93
Cash flow
Cash from operations	(67.71)	(48.60)	(20.56)	(22.92)	(36.62)	(36.68)	(45.15)
Cash from investing	(686)	44.21	(0.68)	(349)	(107)	2.41	42.03
Cash from financing	757	(0.76)	(1.05)	396	146	34.86	3.81

Particulars	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Revenue	1.20	3.57	1.52	2.81	0.92	1.87	1.47	1.61
Revenue growth (YoY)	+30.4%	+90.9%	+3.4%	+74.5%	-64.2%	+85.2%	-	-
Other income	6.73	7.52	6.78	2.77	3.78	0.59	1.19	1.57
Total expenses	21.55	24.58	17.72	17.70	18.83	15.87	16.38	14.91
EBITDA	(20.35)	(21.01)	(16.20)	(14.89)	(17.91)	(14.00)	(14.91)	(13.30)
EBITDA margin	-1695.8%	-588.5%	-1065.8%	-529.9%	-1946.7%	-748.7%	-1014.3%	-826.1%
Depreciation	2.30	2.16	1.58	1.35	1.32	1.37	1.35	1.53
Interest	0.46	0.48	0.16	0.00	0.00	0.00	0.00	0.01
Profit before tax	(16.38)	(16.13)	(11.16)	(13.47)	(15.45)	(14.78)	(15.07)	(13.27)
Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 06 Nov 2026

Particulars	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Revenue	1.20	3.57	1.52	2.81	0.92	1.87	1.47	1.61
Revenue growth (YoY)	+30.4%	+90.9%	+3.4%	+74.5%	-64.2%	+85.2%	-	-
Other income	6.73	7.52	6.78	2.77	3.78	0.60	1.22	1.63
EBITDA	(111)	(132)	(50.63)	(103)	(79.77)	(50.75)	(43.82)	(39.21)
EBITDA margin	-9243.3%	-3711.5%	-3330.9%	-3677.9%	-8670.7%	-2713.9%	-2981.0%	-2435.4%
Depreciation	2.30	2.16	1.58	1.35	1.32	1.37	1.35	1.53
Interest	0.46	0.48	0.16	0.00	0.00	0.00	0.00	0.01
Profit before tax	(107)	(128)	(45.59)	(102)	(77.31)	(51.52)	(43.95)	(39.12)
Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net profit	(107)	(128)	(45.59)	(102)	(77.31)	(51.52)	(43.95)	(39.12)
EPS (₹)	(3.77)	(4.84)	(2.02)	(4.55)	(3.48)	(2.36)	(2.02)	(1.79)

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue	7.11	6.66	11.69	13.54	11.84	13.48	14.41
Revenue growth	+6.8%	-43.0%	-13.7%	+14.4%	-12.2%	-6.5%	-
Other income	13.93	10.90	28.59	14.45	5.32	7.75	14.04
Total expenses	291	172	140	139	134	93.43	130
Employee cost	24.15	20.82	18.99	18.62	21.02	18.53	17.41
EBITDA	(284)	(166)	(128)	(126)	(122)	(79.95)	(116)
EBITDA margin	-3999.4%	-2487.2%	-1093.8%	-928.7%	-1032.5%	-593.1%	-803.0%
Depreciation	5.61	5.82	6.50	6.54	4.39	4.35	4.17
Interest	0.31	0.17	0.30	0.41	0.67	0.94	0.55
Profit before tax	(276)	(161)	(106)	(118)	(122)	(77.49)	(106)
Tax	0.00	0.00	(1.00)	0.00	0.00	(5.32)	(12.18)
Net profit	(286)	(166)	(117)	(126)	(126)	(72.23)	(94.71)
Net profit margin	-4021.0%	-2488.3%	-1001.6%	-930.9%	-1064.0%	-535.8%	-657.3%
EPS (₹)	(10.48)	(7.37)	(4.82)	(5.42)	(8.39)	(5.67)	(7.40)

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Equity & liabilities
Share capital	26.37	21.81	21.81	21.81	14.54	12.73	12.73
Reserves & surplus	410	88.18	248	354	81.61	58.36	131
Shareholders' funds (net worth)	591	110	270	375	96.15	108	143
Minority interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Secured loans	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Unsecured loans	16.69	0.00	0.71	1.61	3.21	4.76	6.01
Total debt	16.69	0.00	0.71	1.61	3.21	4.76	6.01
Total liabilities	610	112	272	379	101	115	152
Assets
Gross block	130	113	78.24	88.60	82.57	67.77	77.32
Net block	72.99	59.65	28.21	37.21	37.56	20.96	24.70
Capital work in progress	3.60	0.01	0.00	0.00	3.55	4.77	0.00
Investments	181	22.28	75.94	46.34	45.16	0.09	0.05
Inventories	0.10	0.24	0.71	0.00	0.02	0.14	0.00
Sundry debtors	1.51	1.34	1.29	0.81	1.30	1.76	2.27
Cash & bank balances	337	37.73	164	184	5.52	46.65	15.09
Loans & advances	26.99	13.89	14.76	20.16	14.59	54.04	48.58
Total current assets	366	53.20	181	205	21.43	103	65.94
Total current liabilities	14.20	23.49	12.81	10.11	6.68	13.86	24.51
Net working capital	352	29.71	168	195	14.75	88.73	41.43
Total assets	610	112	272	379	101	115	152

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Opening cash	15.03	14.93	37.02	5.27	9.35	14.68	0.23
Net cash from operating activities	(300)	(155)	(115)	(116)	(128)	(96.02)	(135)
Net cash from investing activities	(462)	155	94.44	(248)	(22.23)	55.84	146
Net cash from financing activities	757	(0.76)	(1.05)	396	146	34.86	2.81
Net change in cash	(5.23)	(1.12)	(22.09)	31.75	(4.07)	(5.33)	14.45
Closing cash	337	37.73	164	184	5.52	46.65	15.09

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Growth
Sales growth	+6.8%	-43.0%	-13.7%	+14.4%	-12.2%	-6.5%	-
EBITDA growth	-71.7%	-29.6%	-1.7%	-2.9%	-52.9%	+30.9%	-
PBT growth	-71.9%	-51.5%	+10.3%	+3.1%	-57.4%	+27.2%	-
Net income growth	-72.5%	-41.5%	+7.1%	-0.1%	-74.4%	+23.7%	-
Revenue CAGR (3Y)	-19.3%	-17.5%	-4.6%	-2.1%	-65.4%	-72.2%	-70.2%
EBITDA CAGR (3Y)	+31.3%	+10.7%	+17.0%	+2.8%	+104.1%	-	-
Profitability & leverage
Net income margin	-3886.8%	-2413.5%	-898.9%	-873.3%	-1030.3%	-535.4%	-653.8%
Return on capital employed	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Return on net worth	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Debt / equity	0.02	0.00	0.00	0.01	0.04	0.04	0.02
Long-term debt / equity	0.02	0.00	0.00	0.00	0.02	0.03	0.02
Interest cover	-0.11	-0.10	-0.22	-0.31	-0.53	-1.12	-0.46
Efficiency & per share
Fixed asset turnover	0.06	0.07	0.14	0.16	0.16	0.19	0.25
Inventory turnover	41.82	14.02	32.93	1,354.00	148.00	192.57	0.00
Debtors turnover	4.99	5.06	11.13	12.83	7.74	6.69	5.87
EPS (₹)	(10.48)	(7.37)	(4.82)	(5.42)	(8.39)	(5.67)	(7.40)
Dividend per share (₹)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Book value per share (₹)	16.53	5.04	12.38	17.21	6.61	5.58	11.26

Particulars	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Revenue	1.20	3.57	1.52	2.81	0.92	1.87	1.47	1.61
Revenue growth (YoY)	+30.4%	+90.9%	+3.4%	+74.5%	-64.2%	+85.2%	-	-
Other income	6.73	7.52	6.78	2.77	3.78	0.59	1.19	1.57
Total expenses	21.55	24.58	17.72	17.70	18.83	15.87	16.38	14.91
EBITDA	(20.35)	(21.01)	(16.20)	(14.89)	(17.91)	(14.00)	(14.91)	(13.30)
EBITDA margin	-1695.8%	-588.5%	-1065.8%	-529.9%	-1946.7%	-748.7%	-1014.3%	-826.1%
Depreciation	2.30	2.16	1.58	1.35	1.32	1.37	1.35	1.53
Interest	0.46	0.48	0.16	0.00	0.00	0.00	0.00	0.01
Profit before tax	(16.38)	(16.13)	(11.16)	(13.47)	(15.45)	(14.78)	(15.07)	(13.27)
Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue	7.11	6.66	11.69	13.54	11.84	13.48	14.41
Revenue growth	+6.8%	-43.0%	-13.7%	+14.4%	-12.2%	-6.5%	-
Other income	13.91	10.73	28.59	14.45	5.32	7.75	14.04
Total expenses	70.02	58.49	42.54	41.17	48.36	43.93	49.68
Employee cost	24.15	20.82	16.53	15.77	17.46	15.29	14.60
EBITDA	(62.91)	(51.83)	(30.85)	(27.63)	(36.52)	(30.45)	(35.27)
EBITDA margin	-884.8%	-778.2%	-263.9%	-204.1%	-308.5%	-225.9%	-244.8%
Depreciation	5.61	5.82	6.50	6.54	4.39	4.35	4.17
Interest	0.26	0.15	0.24	0.40	0.64	0.91	0.54
Profit before tax	(54.87)	(47.07)	(9.00)	(20.12)	(36.23)	(27.96)	(25.94)
Tax	0.00	0.00	(1.00)	0.00	0.00	(5.32)	(12.18)
Net profit	(64.41)	(52.05)	(20.01)	(27.91)	(36.50)	(22.70)	(14.26)
Net profit margin	-905.9%	-781.5%	-171.2%	-206.1%	-308.3%	-168.4%	-99.0%
EPS (₹)	(2.08)	(2.16)	(0.37)	(0.92)	(2.49)	(1.78)	(1.08)

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Equity & liabilities
Share capital	26.37	21.81	21.81	21.81	14.54	12.73	12.73
Reserves & surplus	1,321	778	824	832	461	352	375
Shareholders' funds (net worth)	1,503	800	845	853	476	402	388
Secured loans	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Unsecured loans	16.69	0.00	0.71	1.61	3.21	4.76	6.01
Total debt	16.69	0.00	0.71	1.61	3.21	4.76	6.01
Total liabilities	1,522	801	847	857	481	408	396
Assets
Gross block	130	113	78.32	88.60	83.40	67.77	77.32
Net block	72.99	59.65	28.21	37.21	37.57	20.96	24.70
Capital work in progress	3.60	0.01	0.00	0.00	3.55	4.77	0.00
Investments	1,094	714	653	528	426	295	242
Inventories	0.10	0.24	0.71	0.00	0.02	0.14	0.00
Sundry debtors	1.51	1.34	1.29	0.81	1.30	1.76	2.27
Cash & bank balances	331	19.96	153	174	3.15	38.59	1.12
Loans & advances	26.99	13.89	14.76	20.16	14.59	54.04	48.55
Total current assets	360	35.43	170	195	19.06	94.53	51.94
Total current liabilities	9.08	7.67	4.05	3.51	5.17	7.18	8.01
Net working capital	351	27.76	166	191	13.89	87.35	43.93
Total assets	1,522	801	847	857	481	408	396

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Opening cash	0.46	4.40	26.70	2.90	1.29	0.71	0.01
Net cash from operating activities	(67.71)	(48.60)	(20.56)	(22.92)	(36.62)	(36.68)	(45.15)
Net cash from investing activities	(686)	44.21	(0.68)	(349)	(107)	2.41	42.03
Net cash from financing activities	757	(0.76)	(1.05)	396	146	34.86	3.81
Net change in cash	3.34	(5.15)	(22.30)	23.79	1.61	0.58	0.69
Closing cash	331	19.96	153	174	3.15	38.59	1.12

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Growth
Sales growth	+6.8%	-43.0%	-13.7%	+14.4%	-12.2%	-6.5%	-
EBITDA growth	-21.4%	-68.0%	-11.7%	+24.3%	-19.9%	+13.7%	-
PBT growth	-16.6%	-423.0%	+55.3%	+44.5%	-29.6%	-7.8%	-
Net income growth	-23.8%	-160.1%	+28.3%	+23.5%	-60.8%	-59.2%	-
Revenue CAGR (3Y)	-19.3%	-17.5%	-4.6%	-2.1%	-65.4%	-72.2%	-70.2%
EBITDA CAGR (3Y)	+31.6%	+12.4%	+0.4%	-7.8%	-	-	-
Profitability & leverage
Net income margin	-771.7%	-706.8%	-68.4%	-148.6%	-306.0%	-168.0%	-95.5%
Return on capital employed	-5.5%	-6.3%	-2.4%	-4.1%	-8.0%	-6.7%	-6.3%
Return on net worth	-5.6%	-6.3%	-2.4%	-4.2%	-8.3%	-5.7%	-3.5%
Debt / equity	0.01	0.00	0.00	0.00	0.01	0.01	0.01
Long-term debt / equity	0.01	0.00	0.00	0.00	0.00	0.01	0.01
Interest cover	-0.38	-0.26	-0.64	-1.17	-1.56	-2.61	-1.37
Efficiency & per share
Fixed asset turnover	0.06	0.07	0.14	0.16	0.16	0.19	0.25
Inventory turnover	41.82	14.02	32.93	1,354.00	148.00	192.57	0.00
Debtors turnover	4.99	5.06	11.13	12.83	7.74	6.69	5.87
EPS (₹)	(2.08)	(2.16)	(0.37)	(0.92)	(2.49)	(1.78)	(1.08)
Dividend per share (₹)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Book value per share (₹)	51.11	36.66	38.77	39.14	32.74	28.66	30.46

Investments & Acquisitions by Suven Life Sciences

Suven Life Sciences has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Asian Clinical Trials and Rising Pharmaceuticals.

Acquisitions

Company Name	Description	Domain	Location	Founded	Acquired	Amount
Rising Pharmaceuticals	Generic and specialty pharmaceuticals are manufactured in various dosage forms.	risingpharma.com	Allendale, United States	1999	Feb 2019	••••
Asian Clinical Trials	Full-service CRO for Phase I-IV clinical trials is offered.	act-india.com	Hyderabad, India	2001	Mar 2006	••••

Premium access

Complete acquisition details for Suven Life Sciences

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

Acquired stakes
Deal sources
Complete history
Exports

Verified entity values are shown only after access is granted.

Timeline of Suven Life Sciences

4 dated milestones of Suven Life Sciences across 30 years, from founding to its latest funding, stage changes and deals.

1989 Founded Suven Life Sciences is founded.
Oct 2003 IPO Lists on the stock exchange (IPO).
Mar 2006 Acquisition Acquires Asian Clinical Trials.
Feb 2019 Acquisition Acquires Rising Pharmaceuticals.

Web traffic of Suven Life Sciences

The website of Suven Life Sciences (suven.com) receives about 4.9K visits a month and ranks #3,256,170 among all websites worldwide, #4,282 in Biotechnology and Pharmaceuticals.

Monthly visits
4.9K
▼ 13.9% vs previous month
Unique visitors
2.5K
per month
Global rank
#3,256,170
among all websites
Category rank
#4,282
Health · Biotechnology and Pharmaceuticals

Visitor engagement

Bounce rate40%
Pages per visit2.0
Average visit37 sec
Devices
Desktop 43% · Mobile 57%

Similar websites

Websites whose visitors overlap most with Suven Life Sciences. Affinity shows how closely the audiences match.

Website	Domain	Audience affinity	Monthly visits	Global rank	Profile
Sms Pharmaceuticals	smspharma.com	100%	3K	#2,783,668	View details
Neuland Labs	neulandlabs.com	91%	20.8K	#904,182	View details
discoverylifesciences.com	discoverylifesciences.com	82%			–
Curia	amriglobal.com	82%	680.7K		View details
Bioplus Life Sciences	bioplus.in	82%	5.9K	#8,003,749	View details
••••••••••	••••••.com	••%	•.•M	#•••••	–
••••••••••	••••••.com	••%	•.•M	#•••••	–
••••••••••	••••••.com	••%	•.•M	#•••••	–

Premium access

All 8 similar websites and full traffic analytics for Suven Life Sciences

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

8 similar websites
Audience overlap
Engagement analytics
Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.

Included in your Premium account

✓
Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
✓
Full access to every database India & global coverage, advanced filters and rich profile details
✓
Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Suven Life Sciences

SUVEN: Q2 CONS NET LOSS 163.8M RUPEES VS LOSS 154.5M (YOY); Q2 REVENUE 12M RUPEES VS 9.2M (YOY)

Exchange Update • 2 days ago

Momentum Stocks: Pix Transmissions, Brightcom Group, Suven Life gain on sheer momentum

Moneycontrol • 2 months ago

How three stubborn men, and $1.5 billion poured in over two decades, put India on the world's new-drug map

Mint • 3 months ago

Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2

Reuters • 4 months ago

Suven Life clears key safety review for Alzheimer's drug, Phase 3 on track

Moneycontrol • 5 months ago

Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study

Reuters • 5 months ago

Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant

Reuters • 11 months ago

Suven Life Sciences Announces First Patient Randomized in Phase-2b Trial

Moneycontrol • 1 year ago

Suven Life Sciences Says First Patient Randomized In Phase-2B Clinical Trial Of Ropanicant

Reuters • 1 year ago

5 top performing pharma stock in last year: Wockhardt, Suven Life Sciences, Blue Jet Healthcare, Indraprastha Medical Corp and Strides Pharma Science make the cut

Moneycontrol • 1 year ago

Premium access

Complete news archive for Suven Life Sciences

Full article history, source details, and older brand coverage require an active premium plan.

Full article archive
Source and publication date
Older coverage
Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Suven Life Sciences

When was Suven Life Sciences founded?

Suven Life Sciences was founded in 1989.

Where is Suven Life Sciences located?

Suven Life Sciences is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

How many employees does Suven Life Sciences have?

Suven Life Sciences has 236 employees.

What is the annual revenue of Suven Life Sciences?

The primary company behind Suven Life Sciences, Suven Life Sciences Limited, reported revenue of ₹21.04 Cr for FY 2026, up 7% year on year.

What does Suven Life Sciences do?

Suven Life Sciences offers a suite of services that include CRAMS, drug discovery (includes internal discovery with their own pipeline) and development support services (DDDSS) and formulation development manufacturing services (FDC) for small molecules. They offer a full range of services in drug discovery, development, and manufacturing. Through their CRAMS services, they offer medicinal chemistry services (Lead optimization, Intermediates Building blocks), preclinical and clinical development support, (custom synthesis, scale-up from g to kg etc.,) and API, intermediate and formulation manufacturing services. They claim to have partnerships with 60 innovator pharma companies for CRAMS initiatives and have completed 600 projects. As part of their DDDSS, they offer bioanalytical services (BABE, SADMAD, toxicology studies etc.), PKPD and ADME services. As part of their FDC services they offer analytical method development validation, stability studies etc., Their facilities have been approved for API and intermediate production by the FDA (formulations also), EDQM, MHRA, and PMDA. The company has a CNS drug discovery collaboration with Eli Lilly. Suven has 11 drugs with out-licensing potential. Suven claims to have partnerships with 61 innovator pharma companies for CRAMS initiatives. The company has 41 product patents and 15 process patents as of Jun-2016 in both developed and developing countries.

What products or services does Suven Life Sciences offer?

Suven Life Sciences offers Drug Discovery Services, Masupirdine, Samelisant, and Analytical Chemistry Services.

Is Suven Life Sciences publicly traded?

Yes, Suven Life Sciences is publicly traded on NSE under the ticker symbol SUVEN.

How many acquisitions has Suven Life Sciences made?

Suven Life Sciences has made 2 acquisitions, including Asian Clinical Trials, and Rising Pharmaceuticals.

Which legal entities are associated with Suven Life Sciences?

Suven Life Sciences operates through Suven Life Sciences Limited.

Who are the directors of Suven Life Sciences?

The legal entities of Suven Life Sciences currently have 8 directors, including Santanu Mukherjee, Mohan Kumar Mallarapu, Sudharani Jasti and others.

About Suven Life Sciences

Company details

Operational Areas of Suven Life Sciences

Associated legal entities of Suven Life Sciences

Products & Services of Suven Life Sciences

Board of directors of Suven Life Sciences Limited (Suven Life Sciences)

People of Suven Life Sciences

Complete people profiles for Suven Life Sciences

IPO & Listings of Suven Life Sciences

Financials of Suven Life Sciences

Financial Highlights

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr Consolidated Standalone AnnualQuarterly

Financial Statements

Investments & Acquisitions by Suven Life Sciences

Complete acquisition details for Suven Life Sciences

Timeline of Suven Life Sciences

Web traffic of Suven Life Sciences

All 8 similar websites and full traffic analytics for Suven Life Sciences

Related news about Suven Life Sciences

Complete news archive for Suven Life Sciences

Frequently Asked Questions about Suven Life Sciences

Financial summary ₹ Cr